近日，总部位于巴黎的生物技术公司Aqemia成功获得3000万欧元的A轮融资，该公司致力于利用生成式AI和量子技术发现和设计新药物。此轮融资由Wendel Growth领投，现有投资者法国VC Eurazeo、公共银行Bpifrance以及Elaia参投。至此，Aqemia的A轮融资总额已达到6000万欧元。
Aqemia公司开发了一种人工智能驱动的技术，该技术能加速分子的发现和设计，这些分子有望成为治疗各类疾病的药物。据悉，该公司已成功利用该技术在药物研发领域取得重要突破。
本次融资将用于进一步推动Aqemia在人工智能药物研发领域的技术创新，加快新药上市的进程。人工智能在药物研发领域的应用正逐渐成为趋势，未来或将对全球医药产业产生深远影响。
英文翻译：
News Title: AI-powered drug discovery startup Aqemia raises €30 million Series A extension
Keywords: AI, drug discovery, biotechnology, financing
News Content:
Paris-based biotechnology company Aqemia has raised a €30 million Series A extension round to continue developing its AI-powered approach to drug discovery and design. The round was led by Wendel Growth with participation from existing investors French VC firm Eurazeo, public bank Bpifrance, and Elaia. With this latest injection of funds, Aqemia’s Series A round has now raised a total of €60 million.
Aqemia has developed an AI-driven technology that accelerates the discovery and design of molecules that could become drugs to treat various diseases. The company has achieved significant breakthroughs in the field of drug discovery using this technology.
The funding will be used to further drive innovation in AI-powered drug discovery at Aqemia and speed up the process of bringing new drugs to market. The application of AI in drug discovery is becoming a trend and is expected to have a profound impact on the global pharmaceutical industry.
【来源】https://sifted.eu/articles/aqemia-60m-series-a
Views: 1